$7.84
+0.53 (+7.25%)
TIC News30 articles
nLIGHT Shares Plunge 24% on Optics Shortage
nLIGHT (LASR) shares fell nearly 24% after the company delayed $17M in product shipments due to an optics shortage, despite record Q2 revenue of $82.6M.
Coherent Soars 41% on Week as U.S. Weighs China Optics Ban
Coherent (COHR) surged 40.7% this week following a U.S. draft proposal to curb Chinese optical transceiver imports, with earnings due Aug 12.
Oklo's Test Reactor Goes Critical, But $4.2B Valuation Gap Looms
Oklo's Groves test reactor reached criticality, a key milestone, yet its $7.19B market cap far exceeds cash on hand, underscoring the need for commercial validation.
Celestica's $3B AI-Fueled Stock Sale Raises Stakes for 2027 Growth
Celestica prices a $3 billion equity offering at $310 per share, a 14.5% discount, to fund AI-driven expansion. Shares fall in premarket trading as investors weigh dilution against 2027 growth prospects.
Datavault AI Shares Tumble 24% as Nasdaq Compliance Clock Ticks
Datavault AI (NASDAQ:DVLT) drops 24% to $0.28, with a Nasdaq compliance deadline looming. The stock must rally 254% by August 11 to meet the $1 minimum bid.
Bluejay Diagnostics Stock Jumps 47% Premarket Despite Warrant Hurdles
Bluejay Diagnostics (BJDX) shares soared 47% premarket, but the rally leaves the stock below the warrant strike price, complicating financing plans.
Coherent Stock Jumps 12% on Report of Possible US Ban on Chinese Optics
Coherent (COHR) shares jumped 12.4% after reports of a proposed US ban on Chinese optical transceivers, boosting market value by $7B. The move highlights potential reshoring of AI optics supply.
Marvell Stock Jumps 11% on AI Memory Expansion, Optics Rally
Marvell (MRVL) shares rose 11% after unveiling new AI-memory products, boosting market value by $19.9B. The rally also lifted optics peers on reports of possible US restrictions on Chinese transceivers.
Applied Optoelectronics Surges 23% on AI Optics Demand
AAOI stock jumped 23% since Friday, adding $1.77B in market value ahead of Q2 earnings. Optical sector rallies on AI infrastructure demand.
Critical Metals Surges 16% on Rare-Earth Policy Momentum
Critical Metals (CRML) stock surged 15.6% Monday, outperforming peers, as policy support for Western rare-earth supply drove investor enthusiasm. The gain added about $126 million to its market value.
TG Therapeutics Stock Drops 9.8% Despite Strong BRIUMVI Sales as Costs Surge
TG Therapeutics shares fell 9.8% as Q2 revenue rose 70% but operating income declined 38% on surging costs. Guidance raised modestly.
Universe Pharmaceuticals Surges 134% After Patent Deal Closes
Universe Pharmaceuticals shares surged over 130% in premarket trading after closing the Best Praise acquisition, which increased its share count nearly eightfold.
Wetour Robotics Soars 145% Before 1-for-100 Reverse Split; Vote on 2 Trillion Share Plan Looms
Wetour Robotics (WETO) surges 145% pre-reverse split; shareholders to vote on 2 trillion share plan and Class B stock with 100 votes per share.
Palantir Faces Valuation Test as AI Strategy Meets Skepticism
Palantir shares hold steady at $122.38 ahead of Monday's earnings, with the stock trading at 41x sales. Options imply a 10% move.
Mangoceuticals Rockets 173% on Nuclear Merger; Existing Holders Left with 4%
Mangoceuticals (MGRX) shares soared 173.5% to $0.8029 after announcing a reverse merger with Nuclea Energy, with existing shareholders retaining only 4% pre-PIPE.
Focus Universal Stock Rockets 651% on AI Debut, But Skeptics Abound
Focus Universal (FCUV) soared 651% after unveiling an AI document platform, but the move is driven by speculation rather than fundamentals, with no revenue details disclosed.
Hims & Hers Plunges 12% as FTC Lawsuit Challenges Data Practices
Hims & Hers Health shares fell 11.9% to $25.83 after the FTC sued over privacy and billing practices, wiping out roughly $800 million in market cap.
Celestica Soars 8% After Raising Full-Year Guidance, Q4 Revenue Implied at $6.35B
Celestica shares surged 8% after raising its 2026 outlook, with Q4 revenue implied at $6.35 billion and adjusted EPS at $3.62, driven by robust AI and cloud demand.
Capricor Therapeutics Plunges 67% on FDA Concerns Over Deramiocel Efficacy
Capricor Therapeutics shares plummeted 67% after FDA staff flagged concerns about deramiocel's efficacy data, wiping out $766 million in market value ahead of a key advisory committee vote.
Joby Aviation Stock Drops 8% as Virgin Atlantic Deal Lacks Financial Details
Joby Aviation shares slid 8.1% on Friday, closing at $6.93, as the Virgin Atlantic agreement lacked specifics on aircraft orders, payments, or launch dates.
Viking Therapeutics Faces Cash Runway Questions Ahead of Q2 Report
Viking Therapeutics shares fell 6.2% last week as analysts increased Q2 loss estimates by 24% to $1.23 per share. The company's cash runway faces scrutiny ahead of earnings on July 29.
Arbe Robotics Slips From Defense Rally, Eyes Q2 Earnings
Arbe Robotics (ARBE) stock retreated from a defense-contract rally, closing at $0.6777 with a 6.7% weekly loss. Q2 earnings on August 6 are the next key event.
Alphabet Shares Dip 7.8% Weekly Despite Friday Uptick, Capex Surge Weighs
Alphabet (GOOGL) shares fell 7.8% for the week despite a slight Friday gain, as Q2 capital expenditures doubled and free cash flow turned negative, overshadowing a $99B equity gain.
Paramount Skydance Faces $1.7 Billion Ticking Fee as Merger Delay Looms
Paramount Skydance faces a $1.7 billion ticking fee as court delays its Warner Bros Discovery merger, representing 18.5% of market cap.
Outlook Therapeutics Halts After Lytenava Approval; Cash Concerns Loom
Outlook Therapeutics (OTLK) shares were suspended after FDA approval of Lytenava for wet AMD. The stock rose 23.5% to $1.63, but funding from warrants and cash burn remain key issues.
BYD Stock Steady as European Gains Offset Domestic Challenges
BYD shares ended the week flat at HK$88.65, as strong European growth offset a sharp decline in China sales.
Rani Therapeutics Soars 29%, Narrows Nasdaq Compliance Gap to 11%
Rani Therapeutics shares jumped 29.4% to $0.89, reducing the gap to Nasdaq's $1 minimum bid to about 11%. CEO Talat Imran's open-market purchase and promising Phase 1a results for RT-114 fueled the rally.
Joby Aviation Gains 2.9% After Inking Exclusive UK Sales Pact with Virgin Atlantic
Joby Aviation shares rose 2.9% premarket after signing an exclusive UK deal with Virgin Atlantic, giving Joby access to Virgin's booking platform while retaining all regulatory and operational duties.
Catalyst Pharmaceuticals Delisted After Angelini Merger Closes
Catalyst Pharmaceuticals was delisted from Nasdaq after Angelini Pharma completed its $4.1 billion acquisition. The stock closed at $31.49, just one cent below the $31.50 cash payout.
Opendoor Technologies Faces Critical $9 Million Profit Gap Ahead of Q2 Earnings
Opendoor Technologies (NASDAQ:OPEN) shares edged up 0.8% to $4.48 in premarket trading as the company approaches a critical Q2 earnings test, needing to close a $9 million gap to reach breakeven.